Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 355.

https://doi.org/10.1182/blood-2019-123930

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Jennifer R Brown, MD PhD, Barbara F. Eichhorst, MD, Paolo Ghia, MD PhD, Arnon P. Kater, MD PhD, Jianyong Li, MD, Sudha Khurana, Mostafa Elhamy, Min Hui Wang, PhD, John F. Seymour, MBBS, PhD FRACP

Blood (2019) 134 (Supplement_1): 4318.

https://doi.org/10.1182/blood-2019-123057

Published: 2019

Journal Articles

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

Anne W. J. Martens, MSc, Susanne R. Janssen, MSc, Ingrid A.M. Derks, Sanne Tonino, MD PhD, Eric Eldering, Gerritje J. W. van der Windt, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 3043.

https://doi.org/10.1182/blood-2019-123350

Published: 2019

Journal Articles

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Sabina Kersting, MD PhD, Mark-David Levin, MD PhD, Carsten Utoft Niemann, MD PhD, Yvette Norden, PhD, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 1753.

https://doi.org/10.1182/blood-2019-124550

Published: 2019

Journal Articles

Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients

Rebecka Svanberg, MD, Sisse Rye Ostrowski, MD PhD DMSc, Ass Prof, Jakob Thaning Bay, MD PhD, Lars Peter Ryder, MSc, PhD, Hanne Vibeke Vibeke Marquart, Arnon P Kater, MD PhD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4289.

https://doi.org/10.1182/blood-2019-123410

Published: 2019

Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Blood (2019) 134 (Supplement_1): 4292.

https://doi.org/10.1182/blood-2019-124377

Published: 2019

Journal Articles

Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2018-99-110327

Published: 2018

Journal Articles

Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Blood (2017) 130 (Supplement 1): 155.

https://doi.org/10.1182/blood.V130.Suppl_1.155.155

Published: 2017

Journal Articles

Impaired Metabolic Fitness in T Cells in Chronic Lymphocytic Leukemia

Armando van Bruggen, MSc, Sanne Endstra, Gerritje J.W. van der Windt, PhD, Arnon P. Kater, MD PhD

Blood (2016) 128 (22): 2528.

https://doi.org/10.1182/blood.V128.22.2528.2528

Published: 2016

Journal Articles

Bcl-2 Members As Drug Target and Biomarkers for Response to Ibrutinib and Venetoclax in CLL

Eric Eldering, PhD, Victor Peperzak, PhD, Hanneke ter Burg, Stacey M. Fernandes, MS, Jennifer R. Brown, MD PhD, Arnon P. Kater, MD PhD

Blood (2016) 128 (22): 2043.

https://doi.org/10.1182/blood.V128.22.2043.2043

Published: 2016

Journal Articles

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Blood (2016) 128 (22): 229.

https://doi.org/10.1182/blood.V128.22.229.229

Published: 2016

Journal Articles

Exome-Wide Sequencing Reveals Oncogenic Mutations in Both Progressive and Non-Progressive MBL

Doreen te Raa, Mark Lanasa, MD PhD, Sallie Allgood, Paula Scotland, Cassie Love, Arend Jan van Houte, Douwe Biesma, Arnon P. Kater, MD PhD, Sandeep Dave, MD

Blood (2015) 126 (23): 361.

https://doi.org/10.1182/blood.V126.23.361.361

Published: 2015

Journal Articles

Targeting BCR-Independent Proliferation of CLL Cells

Slinger Erik, PhD, Arnon P. Kater, MD PhD, Rachel Thijssen, MSc, Eric Eldering, PhD

Blood (2015) 126 (23): 2916.

https://doi.org/10.1182/blood.V126.23.2916.2916

Published: 2015

Journal Articles

Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

Doreen te Raa, Perry Moerland, Alexander Leeksma, Ingrid Derks, Martin Loden, Veronika Navrkalova, Martin Trbusek, PhD, Dieuwertje Luijks, Thorsten Zenz, MD, Anna Skowronska, PhD, Tatjana Stankovic, Mels Hoogendoorn, MD PhD, Marinus H. J. van Oers, Eric Eldering, PhD, Arnon P. Kater, MD PhD

Blood (2015) 126 (23): 2918.

https://doi.org/10.1182/blood.V126.23.2918.2918

Published: 2015

Journal Articles

CLL Disease Severity Is Enhanced in Tcl1 Mice Deficient for Pro-Apoptotic Regulator Noxa

Erik Slinger, PhD, Felix Wensveen, PhD, Arnon P. Kater, MD PhD, Eric Eldering, PhD

Blood (2015) 126 (23): 4144.

https://doi.org/10.1182/blood.V126.23.4144.4144

Published: 2015

Journal Articles

The T-Cell/CLL/Macrophage Triad Shapes a Supportive Tumor Microenvironment in CLL

Martijn H.A. van Attekum, MD, Sanne Terpstra, Emilie Reinen, Marieke Von Lindern, PhD, Erik Slinger, PhD, Eldering Eric, PhD, Arnon P. Kater, MD PhD

Blood (2015) 126 (23): 1715.

https://doi.org/10.1182/blood.V126.23.1715.1715

Published: 2015

Journal Articles

Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed

Iris de Weerdt, Sanne Terpstra, Tom Hofland, Roeland Lameris, MD, Renee C.G. de Bruin, Mark-David Levin, MDPhD, Ester B.M. Remmerswaal, PhD, Ineke J.M. ten Berge, MD PhD, Sanne H. Tonino, MD PhD, Tanja D de Gruijl, PhD, Hans van der Vliet, MD PhD, Arnon P. Kater, MD PhD

Blood (2015) 126 (23): 2914.

https://doi.org/10.1182/blood.V126.23.2914.2914

Published: 2015

Journal Articles

EBV-Specific CD8 + T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia

Tom Hofland, Iris de Weerdt, Sanne Terpstra, Ester B.M. Remmerswaal, PhD, Ineke J.M. ten Berge, MD PhD, Arnon P. Kater, MD PhD, Sanne H. Tonino, MD PhD

Blood (2015) 126 (23): 1723.

https://doi.org/10.1182/blood.V126.23.1723.1723

Published: 2015

Journal Articles

Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform α and δ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation

Rachel Thijssen, Gregor van Bochove, Martin FM de Rooij, Johanna ter Burg, Marcel Spaargaren, PhD, Coumaran Egile, PhD, Marie Jose Kersten, MD PhD, Eric Eldering, PhD, Arnon P. Kater, MD PhD

Blood (2014) 124 (21): 4691.

https://doi.org/10.1182/blood.V124.21.4691.4691

Published: 2014

NARROW

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Impaired Metabolic Fitness in T Cells in Chronic Lymphocytic Leukemia

Bcl-2 Members As Drug Target and Biomarkers for Response to Ibrutinib and Venetoclax in CLL

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Exome-Wide Sequencing Reveals Oncogenic Mutations in Both Progressive and Non-Progressive MBL

Targeting BCR-Independent Proliferation of CLL Cells

Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

CLL Disease Severity Is Enhanced in Tcl1 Mice Deficient for Pro-Apoptotic Regulator Noxa

The T-Cell/CLL/Macrophage Triad Shapes a Supportive Tumor Microenvironment in CLL

Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed

EBV-Specific CD8 + T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia

Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform α and δ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only